June, 2018 | BMT Reviews, Lymphoma, Multiple Myeloma
The goal of this educational program is to improve the treatment of patients with multiple myeloma (MM) and non-hodgkin lymphoma (NHL) through the dissemination of information about stem cell transplantation and mobilization for autologous hematopoietic cell transplantation. The data for stem cell transplantation in MM is rapidly changing. The techniques of mobilization are still evolving.
April, 2017 | Infectious Disease, Lymphoma, MDS / Myeloproliferative, Multiple Myeloma, WebinarsClick the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Speakers Sergio A. Giralt, MD Program Chair Professor of Medicine Weill Cornell College of Medicine Chief Attending, Adult BMT Service Memorial...
July, 2016 | BMT Reviews, Lymphoma
Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.
June, 2015 | BMT Reviews, Lymphoma, Transplantation / Stem Cell
Hematopoietic cell transplantation has become a cornerstone in the management of patients with lymphoma. The use of autologous transplant in Hodgkin’s and non-Hodgkin’s lymphoma has significantly improved the survivals of patients with relapsed disease.
June, 2013 | BMT Reviews, Leukemia, Lymphoma, MDS / Myeloproliferative, Transplantation / Stem Cell
Pre-transplant conditioning can significantly influence post-transplant outcomes. A strong anti-tumor effect achieved by myeloablative conditioning (MAC) is frequently counterbalanced by higher morbidity and non-relapse mortality, particularly in older adults. On the other hand, reduced intensity conditioning (RIC) is associated with lower post-transplant mortality, but may not be sufficient enough to prevent relapse, particularly in patients with persistent and aggressive malignances.
October, 2012 | Leukemia, Lymphoma, Multiple Myeloma, Webinars
According to the American Cancer Society, it was estimated in 2011 there were 44,600 cases of leukemia, 66,360 cases of non-Hodgkin lymphoma, 8,830 cases of Hodgkin lymphoma, and 20,520 cases of myeloma diagnosed for the first time. In addition, the Leukemia and Lymphoma Society estimates that one person is diagnosed with a blood cancer approximately every four minutes in the U.S. The outcome for patients with hematologic malignancies has dramatically changed with the use of novel therapies.